Detecting At-Risk Alzheimer's Disease Cases by Fladby, Tormod et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.3233/JAD-170231
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Fladby, T., Palhaugen, L., Selnes, P., Waterloo, K., Brathen, G., Hessen, E., ... Aarsland, D. (2017). Detecting
At-Risk Alzheimer's Disease Cases. JOURNAL OF ALZHEIMERS DISEASE, 60(1), 97-105. DOI: 10.3233/JAD-
170231
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 06. Nov. 2017
Journal of Alzheimer’s Disease 60 (2017) 97–105
DOI 10.3233/JAD-170231
IOS Press
97
Detecting At-Risk Alzheimer’s
Disease Cases
Tormod Fladbya,b, Lene Pa˚lhaugena,b,∗, Per Selnesa,b, Knut Waterlooc,d, Geir Bra˚thene,f ,
Erik Hessena,g, Ina Selseth Almdahla,b, Kjell-Arne Arntzenc,h, Eirik Auningi,
Carl Fredrik Eliassena,g, Ragna Espenesc,d, Ramune Grambaitea, Gøril Rolfseng Grøntvedte,f ,
Krisztina Kunszt Johansena, Stein Harald Johnsenc,h, Lisa Flem Kalheima,b,
Bjørn-Eivind Kirsebomc,d, Kai Ivar Mu¨llerj,k, Arne Exner Naklingl,m, Arvid Rongven,o,
Sigrid Botne Sandoe,f , Nikias Siafarikasi, Ane Løvli Stava,b, Sandra Tecelaop, Santiago Timona,
Svein Ivar Bekkelundj,k and Dag Aarslanda,m,q
aDepartment of Neurology, Akershus University Hospital, Lørenskog, Norway
bInstitute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway
cDepartment of Neurology, University Hospital of North Norway, Tromsø, Norway
dDepartment of Psychology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway
eDepartment of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian
University of Science and Technology, Trondheim, Norway
fDepartment of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway
gDepartment of Psychology, University of Oslo, Oslo, Norway
hDepartment of Clinical Medicine, Brain and Circulation Research Group, UiT The Arctic University of Norway,
Tromsø, Norway
iDepartment of Geriatric Psychiatry, Akershus University Hospital, Lørenskog, Norway
jDepartment of Neurology and National Neuromuscular Centre, University Hospital of North Norway,
Tromsø, Norway
kDepartment of Clinical Medicine, UiT – The Arctic University of Norway, Tromsø, Norway
lInstitute of Clinical Medicine, University of Bergen, Bergen, Norway
mCentre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway
nDepartment of Research and Innovation, Haugesund Hospital, Helse Fonna, Haugesund, Norway
oDepartment of Clinical Medicine, The University of Bergen, Bergen, Norway
pThe Intervention Centre, Oslo University Hospital, Oslo, Norway
qDepartment of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience,
King’s College London, London, UK
Accepted 22 June 2017
Abstract. While APOE ε4 is the major genetic risk factor for Alzheimer’s disease (AD), amyloid dysmetabolism is an initial
or early event predicting clinical disease and is an important focus for secondary intervention trials. To improve identification
of cases with increased AD risk, we evaluated recruitment procedures using pathological CSF concentrations of A42 (pA)
and APOE ε4 as risk markers in a multi-center study in Norway. In total, 490 subjects aged 40–80 y were included after
response to advertisements and media coverage or memory clinics referrals. Controls (n = 164) were classified as normal
controls without first-degree relatives with dementia (NC), normal controls with first-degree relatives with dementia (NCFD),
or controls scoring below norms on cognitive screening. Patients (n = 301) were classified as subjective cognitive decline or
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mild cognitive impairment. Subjects underwent a clinical and cognitive examination and MRI according to standardized
protocols. Core biomarkers in CSF from 411 and APOE genotype from 445 subjects were obtained. Cases (both self-referrals
(n = 180) and memory clinics referrals (n = 87)) had increased fractions of pA and APOE ε4 frequency compared to NC.
Also, NCFD had higher APOE ε4 frequencies without increased fraction of pA compared to NC, and cases recruited from
memory clinics had higher fractions of pA and APOE ε4 frequency than self-referred. This study shows that memory clinic
referrals are pA enriched, whereas self-referred and NCFD cases more frequently are pA negative but at risk (APOE ε4
positive), suitable for primary intervention.
Keywords: Alzheimer’s disease, amyloid, apolipoprotein E4, biomarkers, cerebrospinal fluid, mild cognitive impairment,
subjective cognitive decline
INTRODUCTION
Alzheimer’s disease (AD) is the major cause of
memory loss and dementia and a main cause for
increasing costs for health care and death. Several
strategies for AD treatment are being pursued, and
early diagnostics and intervention will be necessary.
AD has been shown to encompass long pre-clinical
and pre-dementia periods, but among those seeking
help at memory clinics for early cognitive symp-
toms, non-AD causes (e.g. stress, worrying, and
depression) are predominant [1–3]. Though memory
symptoms are a major cause for concern among the
elderly, few seek medical help for these symptoms
[4]. Better characterization of target groups and more
accurate and efficient screening procedures for early
AD disease activity are crucial to recruit people with
incipient AD and early stage disease for clinical trials.
A long AD pre-dementia period encompassing
amyloid- protein precursor dysmetabolism, amy-
loid plaque formation and inflammation has been
described, initially without subjective cognitive dys-
function, then in some individuals with subjective
cognitive decline (SCD) and ultimately with mild
cognitive impairment (MCI) [2, 5–7]. Several def-
initions of AD manifestations in this period have
been developed. Two pre-clinical AD stages, (1)
asymptomatic amyloidosis and (2) asymptomatic
amyloidosis + neurodegeneration have been sug-
gested as precursors for SCD and MCI [3]. PET
amyloid imaging and cerebrospinal fluid (CSF)
amyloid- (A)42 measurements are considered as
equivalent biomarkers for brain amyloid deposition,
though the CSF measure of low CSF A42 (pA)
has been reported to give an earlier signal [8]. Sub-
tle loss of grey and white matter integrity is closely
coupled to cognitive impairment in the pre-dementia
AD stage [9, 10]. The apolipoprotein E (APOE) ε4
allele is a well-established genetic risk factor for AD,
and several polymorphisms associated with AD have
been related to A metabolism [11–16]. The exact
mechanisms causing early neurodegeneration remain
to be established, but most current treatment trials
focus on altering amyloid metabolism at the MCI
stage [17, 18].
The brain has extensive compensatory mech-
anisms for gradually acquired neuronal damage.
Realizing that not only dementia, but also MCI
appears late in the AD disease process, the prevalence
of AD-like pathology among cognitively normal
cases has attracted increased interest and some data
has been published [19, 20].
We aimed to identify subjects suitable for primary
AD intervention studies, and therefore investigated
whether recruitment strategies focusing on self-
referred cases with cognitive symptoms and ordinary
referrals to memory clinics identified cases with
pA and at-risk subjects without AD pathology
differently.
METHODS
As part of “Dementia Disease Initiation” (DDI),
a co-operation between all Norwegian health
regions and university hospitals, subjects with self-
reported cognitive reduction and healthy controls
were recruited from January 2013 till January
2017 and examined following a standard protocol.
Anonymized data were collected in a customized
database. Recruitment was based on two main
sources: 1) Cases were self-referred following adver-
tisements in media, newspapers or news bulletins,
or 2) recruited among referrals to local memory
clinics. In addition, cognitively healthy controls
were also included from spouses of patients with
dementia/cognitive disorder, and from patients who
completed lumbar puncture for orthopedic surgery.
Participants were staged as controls, SCD or MCI
using published criteria based on the comprehensive
assessment program (see below) [5, 21]. The controls
were further classified as having normal or abnormal
cognitive screening and with or without first-degree
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relative with dementia. Criteria for inclusion were
age between 40 and 80 and a native language of Nor-
wegian, Swedish, or Danish. Exclusion criteria were
brain trauma or disorder, including clinical stroke,
dementia, severe psychiatric disease, severe somatic
disease that might influence the cognitive functions,
or intellectual disability or other developmental dis-
orders.
A case report form was developed which included
medical history from subject and informant, and
physical and neurological examinations including
cognitive examination and the 15-item Geriatric
Depression Score (GDS) [22]. Educational levels
were operationalized according to normative clas-
sification [23]; 0 = Primary school (7–8 y), 1 = High
School (9–11 y), 2 = College (12 y), 3 = Bachelor
degree (13–15 y), 4 = Master or equivalent (16–17 y),
5 = Higher university degree/PhD (18–20 y). The
cognitive examination included the Mini Mental State
Examination (MMSE-NR) [24], non-verbal cogni-
tive screening (the clock drawing test) [25], verbal
memory (CERAD word list) [26], visuoperceptual
ability (VOSP silhouettes), psychomotor speed and
divided attention (Trail making A and B and word
fluency (COWAT) [27].
All subjects gave their written consent, and
the Regional Committee for Medical and Health
Research Ethics South-East evaluated (based on the
Norwegian Health and Research Act and the Helsinki
Declaration of 1964; revised 2013) and approved the
study. All further study conduct was in line with these
guidelines.
Cognitive staging
Symptomatic subjects with normal performance
on standardized tests were classified as SCD, as
defined in the framework by the working group of
SCD [5]. The NIA-AA criteria for MCI were used
for cases with lower performance than expected in
one or more cognitive domains, but yet preserved
independence in functional ability and not fulfill-
ing the criteria of dementia, as defined in NIA-AA
guidelines [21, 28]. Performance was classified as
normal or abnormal according to published norms for
the different tests [24–27, 29–31]. The cutoff values
for SCD versus MCI (defined as normal or abnor-
mal cognition) were results equal to or 1.5 standard
deviation below normative mean on either CERAD
word list (delayed recall), VOSP silhouettes, TMT-
B or COWAT, or having MMSE score equal to or
below 27. Cognitive functioning was also assessed
by the Clinical Dementia Rating scale (CDR) [32].
Cases with dementia were excluded if CDR was
>0.5 [33].
Biomarkers
Lumbar puncture was performed before noon, and
CSF was collected in polypropylene tubes (Thermo
Nunc) and centrifuged within 4 h at 2000 g for 10 min
at room temperature. The supernatant was transferred
to new tubes and frozen at –80°C prior to analysis.
All CSF samples were analyzed at the Department
of Interdisciplinary Laboratory Medicine and Med-
ical Biochemistry at Akershus University Hospital,
and samples from other sites were frozen before
sending to this laboratory. CSF A42, total tau, and
phosphorylated tau were determined using ELISA
(Innotest -Amyloid (1–42), Innotest h-Tau Ag
and Innotest Phospho-Tau (181P), Fujirebio, Ghent,
Belgium).
APOE genotyping was performed on EDTA
blood samples either at Akershus University Hos-
pital (Gene Technology Division, Department of
Interdisciplinary Laboratory Medicine and Medical
Biochemistry) according to the laboratory’s rou-
tine protocol using real-time PCR combined with a
TaqMan assay (Applied Biosystems, Thermo Fisher
Scientific, Waltham, USA) or at the University Hos-
pital of Trondheim according to the protocol for the
Fast Start DNA Master HybProbe Kit (Roche, Basel,
Switzerland) in combination with the LightMix
ApoE C112R R158C kit from TiB MolBiol (Berlin,
Germany) followed by LightCycler technology
(Roche, Basel, Switzerland).
All subjects were referred to an MRI scan, and if
available also to FDG-PET and amyloid PET.
Data analysis
The subjects with cognitive symptoms were cate-
gorized both by stage (Table 1) and by recruitment
method (Table 2). The derived variable “APOE
ε4 positive” was defined as having at least one
APOE ε4 allele. The CSF A42 measurements were
dichotomized using a threshold of 708 ng/L, with
values below the threshold defined as positive. This
current CSF A42 threshold for research use was
determined based on best fit to flutemetamol PET
results (based on 42 subjects for whom CSF and
flutemetamol PET was available, of whom 16 sub-
jects was flutemetamol PET positive and 26 subjects
was flutemetamol PET negative), as described in [34]
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Table 1
Demographic characteristics, cognitive test results, APOE alleles and CSF A pathology of the control and symptomatic subjects classified
by cognitive stage
Control subjects Subjects with cognitive
symptoms
Total Without With family Abnormal SCD MCI
family history cognitive
History Screening
Age at inclusion (SD) 62.9 (9.4) 63.2 (9.6) 58.9 (8.9) 65.2 (7.6) 62.3 (8.9) 65.4 (9.8)
n = 463 n = 46 n = 86 n = 32 n = 163 n = 136
p< 0.05a p = n.s.a p = n.s.a p = n.s.a
Female/Total 253/465 22/46 53/86 21/32 93/164 64/137
54.4% 47.8% 61.6% 65.6% 56.7% 46.7%
p = n.s.c p = n.s. c p = n.s.c p = n.s.c
Education level (IQR) 3.0 (1.0) 3.0 (2.0) 3.0 (2.0) 2.0 (2.0) 3.0 (3.0) 3.0 (2.0)
n = 461 n = 46 n = 85 n = 31 n = 163 n = 136
p= 0.05b p = n.s.b p = n.s.b p = n.s.b
MMSE (IQR) 29.0 (2.0) 29.0 (1.0) 30.0 (1.0) 28.0 (2.0) 29.0 (1.0) 28.0 (3.0)
n = 461 n = 45 n = 86 n = 32 n = 163 n = 135
p = n.s.b p< 0.001b p = n.s.b p< 0.001b
CERAD word list recall 48.9 (14.0) 50.1 (13.6) 57.9 (8.7) 48.3 (11.5) 53.1 (10.3) 37.5 (14.4)
T-score (SD) n = 453 n = 45 n = 85 n = 32 n = 161 n = 130
p< 0.01a p = n.s.a p = n.s.a p< 0.001a
VOSP silhouettes 49.2 (11.1) 50.6 (8.0) 53.8 (9.2) 43.1 (13.6) 52.3 (9.8) 43.6 (10.9)
T-score (SD) n = 419 n = 38 n = 82 n = 29 n = 143 n = 127
p = n.s.a p< 0.05a p = n.s.a p< 0.001a
TMT-B 47.5 (10.2) 53.7 (8.3) 50.5 (8.9) 44.2 (7.9) 49.6 (8.7) 41.3 (11.0)
T-score (SD) n = 443 n = 43 n = 84 n = 32 n = 161 n = 123
p = n.s.a p< 0.001a p< 0.05a p< 0.001a
COWAT 48.9 (9.8) 51.1 (6.8) 50.2 (8.1) 43.7 (10.1) 51.5 (9.9) 45.6 (10.1)
T-score (SD) n = 452 n = 44 n = 84 n = 32 n = 160 n = 132
p = n.s.a p< 0.01a p = n.s.a p< 0.001a
GDS score (IQR) 1.0 (3.0) 0.0 (1.0) 0.0 (1.0) 0.5 (1.0) 2.0 (3.0) 3.0 (3.0)
n = 448 n = 45 n = 81 n = 32 n = 156 n = 134
p = n.s.b p = n.s.b p< 0.001b p< 0.001b
APOE ε4 positivity 196/430 9/43 45/82 12/32 64/147 66/126
45.6% 20.9% 54.9% 37.5% 43.5% 52.4%
p< 0.001c p = n.s.c p< 0.01c p< 0.001c
APOE ε4 allele frequency 25.7% 10.5% 28.7% 20.3% 24.8% 31.3%
p< 0.01c p = n.s.c p< 0.01c p< 0.001c
APOE n = 430 n = 43 n = 82 n = 32 n = 147 n = 126
ε2/ε2 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
– – – –
ε2/ε3 35 (8.1%) 7 (16.3%) 2 (2.4%) 6 (18.8%) 14 (9.5%) 6 (4.8%)
p< 0.01d p = n.s.c p = n.s.d p< 0.05d
ε3/ε3 199 (46.3%) 27 (62.8%) 35 (42.7%) 14 (43.8%) 69 (46.9%) 54 (42.9%)
p< 0.05c p = n.s.c p = n.s.c p< 0.05c
ε2/ε4 15 (3.5%) 1 (2.3%) 6 (7.3%) 1 (3.1%) 3 (2.0%) 4 (3.2%)
p = n.s.d p = n.s.d p = n.s.d p = n.s.d
ε3/ε4 156 (36.3%) 8 (18.6%) 37 (45.1%) 10 (31.3%) 52 (35.4%) 49 (38.9%)
p< 0.01c p = n.s.c p< 0.05c p< 0.05c
ε4/ε4 25 (5.8%) 0 (0.0%) 2 (2.4%) 1 (3.1%) 9 (6.1%) 13 (10.3%)
p = n.s.d p = n.s.d p = n.s.d p< 0.05d
CSF A42 positivity 89/393 2/39 4/62 6/25 24/145 53/122
22.7% 5.1% 6.5% 24.0% 16.6% 43.4%
p = n.s.d p< 0.05d p = n.s.c p< 0.001c
Continuous variables of assumed normal distribution (age at inclusion, CERAD word list recall T-score, VOSP silhouettes T-score, TMT-B
T-score, and COWAT T-score) are summarized by mean (standard deviation) and compared with one-way ANOVA with predefined contrasts
(a). Continuous variables of non-normal distribution (MMSE and GDS) and the ordinal variable (education level) are described by median
(interquartile range) and compared with Mann-Whitney U tests (b). Binary variables (sex, APOE ε4 positivity, APOE ε4 allele frequency,
APOE allele distribution and CSF pA positivity) are described with observed numbers and percentages and compared with Pearson’s Chi
square tests (c) or Fisher’s exact tests when expected count is less than 5 (d).
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Table 2
Demographic characteristics, distribution of cognitive stage (SCD, MCI) for symptomatic subject groups, APOE alleles and CSF A
pathology of the control and symptomatic subjects classified by recruitment method
Control subjects Subjects with cognitive symptoms
Without With Abnormal Recruited Self- Memory Self-versus
family family cognitive as control referral clinic memory
history history screening subjects referral clinic referral
Age at inclusion (SD) 63.2 (9.6) 58.9 (8.9) 65.2 (7.6) 66.6 (6.5) 64.4 (9.7) 61.5 (9.1) p< 0.05a
n = 46 n = 86 n = 32 n = 11 n = 179 n = 86
p< 0.05a p = n.s.a p = n.s.a p = n.s.a p = n.s.a
Female/Total 22/46 53/86 21/32 5/11 97/180 46/87 p = n.s.c
47.8 % 61.6 % 65.6 % 45.5 % 53.9 % 52.9 %
p = n.s.c p = n.s.c p = n.s.c p = n.s.c p = n.s.c
Education level (IQR) 3.0 (2.0) 3.0 (2.0) 2.0 (2.0) 2.0 (2.0) 3.0 (2.0) 2.5 (2.0) p< 0.01b
n = 46 n = 85 n = 31 n = 11 n = 179 n = 86
p= 0.05b p = n.s.b p = n.s.b p = n.s.b p = n.s.b
MMSE (IQR) 29.0 (1.0) 30.0 (1.0) 28.0 (2.0) 27.5 (2.0) 29.0 (2.0) 29.0 (3.0) p< 0.05b
n = 45 n = 86 n = 32 n = 10 n = 179 n = 86
p = n.s.b p< 0.001b p< 0.001b p< 0.05b p< 0.001b
SCD – – – 3/11 110/180 41/87 p< 0.05c
27.3 % 61.1 % 47.1 %
MCI – – – 8/11 70/180 46/87 p< 0.05c
72.7 % 38.9 % 52.9 %
APOE ε4 positive 9/43 45/82 12/32 2/11 71/160 50/79 p< 0.01c
20.9 % 54.9 % 37.5 % 18.2 % 44.4 % 63.3 %
p< 0.001c p = n.s.c p = n.s.d p< 0.01c p< 0.001c
APOE ε4 allele frequency 10.5 % 28.7 % 20.3 % 9.1 % 25.0 % 38.0 % p< 0.01c
p< 0.01c p = n.s.c p = n.s.d p< 0.05c p< 0.001c
CSF A42 positive 2/39 4/62 6/25 1/11 37/155 29/79 p< 0.05c
5.1 % 6.5 % 24.0 % 9.1 % 23.9 % 36.7 %
p = n.s.d p< 0.05d p = n.s.d p< 0.01c p< 0.001c
The continuous variable of assumed normal distribution (age at inclusion) is summarized by mean (standard deviation) and compared
with one-way ANOVA with predefined contrasts (a). The continuous variable of non-normal distribution (MMSE) and the ordinal variable
(education level) are described by median (interquartile range) and compared with Mann-Whitney U tests (b). Binary variables (sex, APOE
ε4 positivity, APOE ε4 allele frequency, and CSF pA positivity) are described with observed numbers and percentages and compared with
Pearson’s Chi square tests (c) or Fisher’s exact tests when expected count is less than 5 (d).
(sensitivity = 0.93, specificity = 0.93, AUC = 0.985;
final results are due for publication in Kalheim et al.,
in submission).
For continuous variables with assumed normal dis-
tribution (age at inclusion, CERAD word list recall
T-score, VOSP silhouettes T-score, TMT-B T-score,
and COWAT T-score) means for the different groups
were compared with one-way ANOVA (analysis of
variance) with pre-defined contrasts. Normality was
assessed by visual inspection of frequency distribu-
tions, Q-Q-plots, and box-plots. Equal variance was
assumed for all except CERAD word list delayed
recall, VOSP silhouettes, and COWAT T-score, given
by Levene’s test. Continuous variables of non-normal
distribution (MMSE and GDS) were compared with
Mann-Whitney U tests, and education level was also
tested with Mann-Whitney U, being an ordinal vari-
able. The binary variables (sex, APOE ε4 positivity,
APOE ε4 allele frequency, APOE allele distribu-
tion, and CSF pA positivity) were compared with
Pearson’s Chi square test or Fisher’s exact test when
expected counts were less than 5. All analyses were
performed in the Statistical Package for Social Sci-
ences version 24 (Chicago, IL, USA).
RESULTS
Of 577 cases considered, 87 withdrew before fin-
ishing the assessment program or did not fulfill the
inclusion criteria (see Fig. 1). Of the 490 cases
included, 465 were staged at the time of analysis.
46 were normal controls without (NC, age 63.2, SD
9.6) and 86 with first degree relative with dementia
(NCFD, age 58.9, SD 8.9), 32 subjects were controls
with abnormal cognitive screening (ACS, age 65.2,
SD 7.6), 164 were SCD (age 62.3, SD 8.9), and 137
were MCI (age 65.4 SD, 9.8). Further characteristics
are shown in Table 1.
Out of 411 cases with available CSF A42 values,
96 had increased fractions of pA (23.4%). 5.1%
of the normal control, 6.5% of controls with first-
degree relatives, and 16.6% of the SCD cases were
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Fig. 1. Initially 577 subjects were considered for inclusion, whereof 87 did not fulfill inclusion criteria or withdrew before finishing the
assessment program. 465 subjects were staged, as either normal controls (NC), normal controls with first degree relative (NCFD), controls
with abnormal cognitive screening results (ACS), subjective cognitive decline (SCD) or mild cognitive impairment (MCI). At the time of
analysis, APOE genotyping was available for 445 subjects, whereof 202 were APOE ε4 positive. Cerebrospinal fluid data was available for
411 subjects, whereof 96 subjects had pathological levels of A42.
pA, compared to 43.3% of MCI cases (p < 0.001
MCI versus NC, Table 2). Out of 445 cases with
available APOE ε4 status, 243 were negative and
202 were positive. In the NC group, 20.9% were
APOE ε4 allele positive (close to population normal),
whereas in the NCFD, ACS, SCD, and MCI group
54.9% (p < 0.001), 37.5% (p = n.s.), 43.5% (p < 0.01),
and 52.4% (p < 0.001) were APOE ε4 allele positive,
respectively when compared to the NC group.
When the symptom subjects were stratified based
on family history of dementia, there were 74 SCD
subjects without and 90 SCD subjects with family
history and 95 MCI subjects without and 42 MCI
subjects with family history. There were no signifi-
cant differences in age, gender, cognitive test results,
APOE positivity, or CSF A42 positivity when SCD
subjects with and without family history or MCI sub-
jects with and without family history were compared
(data not shown).
In the cognitive symptom group (SCD+MCI)
23.9% of self-referred cases had pA, compared to
36.7% in the group referred from memory clinics,
which is significantly higher fractions than the NC
group (p < 0.01 and p < 0.001, respectively). Simi-
larly, in this self-referred group 44.4% were APOE
ε4 allele positive and 63.3% of those referred to
memory clinics, which is significantly more than in
the NC group (p < 0.01 and p < 0.001, respectively)
(Table 2).
Comparing the two recruitment sources, there
was a significantly higher percentage of CSF pA
and APOE ε4 allele carriers in the group referred
to memory clinic compared to self-referred sub-
jects (p < 0.05 and p < 0.01, respectively). There were
also significant differences in age (p < 0.05), educa-
tion level (p < 0.01), MMSE (p < 0.05), and fractions
of SCD and MCI (p < 0.05) between these two
groups.
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DISCUSSION
The DDI project examines incipient disease
activity and AD risk factors in pre-dementia and
presumptive pre-disease patient and control cohorts.
Here, we compared our recruitment strategies to
find optimal cohorts consisting of pre-disease at-risk
cases and pre-dementia cases with signs of amyloid
deposition (Table 2). Compared to NC, we found
increased pA frequencies in both the self-referred
and memory clinic-referred groups. Age did not dif-
fer significantly between these groups, and relevant
patient concern connected to underlying pathology
may have been a factor driving recruitment also in
the self-referred group.
As expected, frequencies of pA differed signif-
icantly between the control groups and SCD cases
compared to MCI cases. Furthermore, while self-
and memory clinic-referrals frequently had pA,
the group referred to memory clinics had clearly
higher proportions than the self-referral group and
are preferred as a source for secondary prevention
treatment trials. Controls with first-degree relatives
with dementia did not have an increased fraction of
pA, but harbored an increased frequency of risk
APOE ε4 alleles compared to controls without. Self-
referred cases were also at-risk, enriched for APOE ε4
alleles, and pA negative. Thus, the majority among
of SCD cases, self-referred cases and NCFD are suit-
able for primary intervention.
These differences in pA fractions were not mir-
rored in APOE ε4 allele frequencies. Both the
self-referred group and the group referred to memory
clinics had significantly higher frequencies, as had the
control group with first-degree relatives with demen-
tia indicating that all these groups are at increased
risk for AD dementia. Though MCI cases had signifi-
cantly lower MMSE-scores (and a higher age), APOE
ε4 allele frequencies were not significantly different
compared to SCD and first degree-relative control
cases (data not shown). APOE ε4 allele frequency was
higher in our control groups overall than expected
from published Norwegian population frequencies
established from healthy blood donors (22.0% com-
pared to 19.8% allele frequency). The NC group
(without first degree relatives with dementia) had a
lower APOE ε4 allele frequency than previously pub-
lished for an equivalent control group (10.5% versus
14.3%), but close to the frequency in our orthopedic-
surgery control cases (11.5%), suggesting that this
level may be realistic for the present population
[35, 36].
To some extent, inclusion strategies and selection
of cutoff levels will always cause bias. The present
CSF A42 cutoff gives the best fit to flutemetamol
PET in (Kalheim et al., in submission). Highly stan-
dardized pre-analytical procedures and laboratory
handling procedures may have contributed to numer-
ically high values. Clinical follow-up is necessary
for ultimate evaluation of CSF A cutoff levels with
the highest predictive power for dementia. Herein,
and for other research purposes (inclusion of patients
for longitudinal studies or for secondary interven-
tion), a relatively high cutoff allowing for sensitive
inclusion of patients at risk (few false negatives) may
be beneficial, whereas for clinical purposes fewer
false positives may be optimal.
One limitation of this study is the specific men-
tion of first-degree relatives in the advertisements.
As such, the present control group has a larger pro-
portion of subjects with first-degree relatives with
dementia. Because of this, we have split the control
group and this has enabled us to specifically examine
first-degree relatives.
In summary, symptomatic cases, both self- and
memory clinic-referrals, harbor an increased propor-
tion of cases with incipient AD pathology compared
to the normal control group without first-degree
relatives with dementia. Controls with first-degree
relatives with dementia do not have an increased
fraction of pA, but harbor an increased frequency
of risk APOE ε4 alleles. There were significantly
higher fractions of subjects with pA, APOE ε4 allele
carriers and MCI subjects in the group referred from
memory clinic compared to self-referred subjects.
Whereas memory clinic referrals are most enriched
for cases amenable for secondary intervention stud-
ies, self-referred cases are enriched for at-risk,
pA negative cases, putatively suitable for primary
intervention.
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